
Sycai Medical is a Barcelona-based tech startup founded in 2020 that develops AI-powered medical device software to assist radiologists in the early detection and characterization of abdominal cancer lesions, primarily focusing on the pancreas with plans to expand to liver and kidneys. Their AI solution integrates seamlessly into hospital PACS workflows, automates lesion tracking over time, and is clinically validated with over 300,000 images trained and presence in 10+ hospital sites. The company holds international patents and complies with ISO 13485, MDR, GDPR, and DICOM standards, aiming to improve diagnostic precision, reduce radiologist burnout, and enable earlier cancer diagnosis to improve patient outcomes.

Sycai Medical is a Barcelona-based tech startup founded in 2020 that develops AI-powered medical device software to assist radiologists in the early detection and characterization of abdominal cancer lesions, primarily focusing on the pancreas with plans to expand to liver and kidneys. Their AI solution integrates seamlessly into hospital PACS workflows, automates lesion tracking over time, and is clinically validated with over 300,000 images trained and presence in 10+ hospital sites. The company holds international patents and complies with ISO 13485, MDR, GDPR, and DICOM standards, aiming to improve diagnostic precision, reduce radiologist burnout, and enable earlier cancer diagnosis to improve patient outcomes.
Location: Barcelona, Catalonia, Spain
Sector: AI medical imaging (radiology software)
Product focus: AI-assisted detection and characterization of abdominal (pancreas) lesions integrated with PACS
Scale: Reported headcount 11–50 (employee_count ~19 in one source)
Funding: Series A announced Jan 23, 2025 (multiple investors including LUMO labs, Ship2B Ventures)
Early detection and characterization of abdominal (pancreatic) lesions and radiology workflow automation.
2020
Healthtech / Medical Imaging
3,000
Recorded small grant from Hospitales San Roque
780,000
Round lists multiple investors including Namarel Ventures and Athos Capital
“Presence of institutional investors (LUMO labs, Ship2B Ventures, Athos Capital, Namarel Ventures) participating in Series A”